9 hours ago
1
tang90246
- The U.S. FDA has approved Ascendis Pharma's (ASND) Skytrofa (lonapegsomatropin) as a once-weekly treatment for adults with growth hormone deficiency (GHD).
- Skytrofa, which acts as a replacement of endogenous growth hormone, was previously approved by the agency in 2021 as a pediatric
English (US) ·